# Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy

> **NCT02144077** · PHASE3 · COMPLETED · sponsor: **Biofrontera Bioscience GmbH** · enrollment: 281 (actual)

## Conditions studied

- Basal Cell Carcinoma (BCC)

## Interventions

- **DRUG:** BF-200 ALA
- **DRUG:** methyl-aminolevulinate

## Key facts

- **NCT ID:** NCT02144077
- **Lead sponsor:** Biofrontera Bioscience GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-28
- **Primary completion:** 2015-11-17
- **Final completion:** 2020-09-09
- **Target enrollment:** 281 (ACTUAL)
- **Last updated:** 2022-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02144077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02144077, "Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02144077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*